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Objectives. To investigate the proportion of diﬀerent genotypes in countryside microregions in southern Brazil, and their
association with risk factors. Methods. Cross-sectional study including a convenience sample of patients who tested positive for
HCV-RNA and were referred to a regional health center for genotyping, from December 2003 to January 2008. Data were obtained
through the National Disease Surveillance Data System, from laboratory registers and from patient charts. Identiﬁcation of
genotypes was carried out using the Restriction Fragment Length Polymorphism “in house” technique. Independent associations
with genotypes were evaluated in multinomial logistic regression and prevalence rates of genotypes were estimated with modiﬁed
Poisson regression. Results. The sample consisted of 441 individuals, 41.1 ± 12.0 years old, 56.5% men. Genotype 1 was observed
in 41.5% (95% CI 37.9–48.1) of patients, genotype 2 in 19.3% (95% CI 15.0–23.6), and genotype 3 in 39.2% (95% CI 35.6–43.0).
HCV genotype was signiﬁcantly associated with gender and age. Dental procedures were associated with higher proportion of
genotype 2 independently of age, education, and patient treatment center. Conclusions. The hepatitis C virus genotype 1 was the
most frequent. Genotype 2 was associated with female gender, age, and dental procedure exposition.
1.Background
Hepatitis C virus (HCV) was identiﬁed in 1989 and has
been considered a major cause of chronic liver disease
worldwide [1]. There is a great variability in its geographical
distribution, associated to the degree of nation development.
High prevalence is found in Africa and Asia, in opposite to
low-prevalence areas localized in industrialized nations in
North America, north and west Europe, and Australia [2–4].
In Brazil, according to the World Health Organization, the
e s t i m a t e dp r e v a l e n c er a n g e sf r o m2 . 5t o4 . 9 %[ 5].
Transmission of HCV has been mainly related to
intravenous drug use since blood products transmission
has decreased in most developed countries. On the other
hand, contaminated injection equipment appears to be the
major risk factor for HCV infection in several countries
and sharing personal hygiene objects might explain the
transmission of virus C to those not infected by the usual
routes [6]. The distribution of diﬀerent genotypes also varies
according to the studied population and viral transmission
risk factors. In studies from Spain there is a predominance
of genotypes 1a and 1b [7, 8] while in other European
regions genotype 2 is usually the most prevalent [4, 9–11].
Genotype 1 predominates in Central America [12], and in
Latin-American countries such as Argentina [13, 14]a n d
Venezuela [15] genotypes 1 and 2 account for 90% of cases.
In Brazil, genotypes 1 and 3 are the most frequent [16, 17],
but in Da Silva et al. study [18] almost half of the hepatitis2 The Scientiﬁc World Journal
Table 1: Sociodemographic characteristics of hepatitis C virus infected patients according to genotype.
Characteristics N∗ Genotype 1 Genotype 2 Genotype 3 P value
N (%) N (%) N (%)
Male 249 116 (46.6) 40 (16.1) 93 (37.3)
0.028 Female 192 67 (34.9) 45 (23.4) 80 (41.7)
White color 389 152 (39.1) 81 (20.8) 156 (40.1)
0.012 Nonwhite color 38 24 (63.1) 3 (7.9) 11 (28.9)
Education
0.079 0–3 years 54 24 (44.4) 14 (25.9) 16 (29.6)
4–11 years 220 89 (40.5) 38 (17.3) 93 (42.3)
College 57 22 (38.6) 18 (31.6) 17 (29.8)
Age
441 <0.001 18–40 years 79 (51.1) 18 (11.6) 58 (37.4)
>40–60 years 92 (39.9) 51 (21.6) 93 (39.4)
>60 years 12 (24.0) 16 (32.0) 22 (44.0)
C patients from South of Brazil were infected by genotypes
2 and 3. In this study we investigated the proportion of
diﬀerent genotypes in countryside microregions of a state
in southern Brazil, and their association with sociodemo-
graphic characteristics and HCV infection risk factors.
2. Methods
A cross-sectional study included a nonprobabilistic sample
of patients under followup at the HCV program of Brazilian
Public Health System, in countryside cities of southern
Brazil.PatientsfromtheBrazilianPublicHealthSystem,who
tested positive for anti-HCV, were referred for genotyping,
from December 2003 to January 2008, to a main regional
health center in the southernmost state of Brazil. Genotyp-
ing was routinely performed to choose the recommended
treatment according HCV genotype. HCV-RNA was carried
out as a conﬁrmatory test and the samples of all patients
genotyped at the central laboratory in the period were
included consecutively.
Retrospective data collection was carried out and
included demographic and socioeconomic characteristics,
exposure and behavioral risks factors. Data were obtained
through the National Disease Surveillance Data System
(SINAN), laboratory registers and from patient charts at
their cities of origin. Researchers were trained before data
collection start, and quality control was performed by
random repetition of data collection in 10% of the sample.
Identiﬁcation of genotypes was carried out using the
Restriction Fragment Length Polymorphism “in house”
technique [19], which uses universal primers and real
time-polymerase chain reaction to amplify speciﬁc genomic
sequences and it compares to strip hybridization. Next,
DNA fragments of diﬀerent sizes are generated by enzymatic
restriction digestion, which recognizes speciﬁc cleavage sites
for each genotype. This method allows diﬀerentiation of
g e n o t y p e s1 ,2 ,3 ,4 ,5 ,a n d6[ 20]. Preanalytic quality
control included the sample and the reagents preparation,
ampliﬁcation and detection, and environment control.
The study has been performed according to the World
Medical Association Declaration of Helsinki and approved
by the Ethics Committee of Passo Fundo University, Brazil.
Regional health centers consented with the study, and an
agreement on data use was signed.
Asamplesizeof384individualswasnecessarytoestimate
a genotype 1 prevalence of 50%, with a 95% conﬁdence
interval and a 10% prevalence variation. Considering the
less expected genotype 2, 292 patients would be necessary to
determine 5%±5p r e v a l e n c e .
Data was described using frequency and central tendency
measures, and 95% conﬁdence intervals were calculated
whenapplicable.Associationsbetweenriskfactorsandgeno-
typewereanalyzedusingchi-square.Toidentifyindependent
associations with genotype we used multinomial logistic
regression. Models were tested taking into account variables
with a P value < 0.20 on the crude analysis, and those
that remained independently associated with the genotype
were included in the ﬁnal model. To explore risk factors
that could be associated with the prevalence of genotype 2,
genotypes 1 and 3 were grouped in the reference category,
and adjusted prevalence ratio was calculated using modiﬁed
Poisson regression, in a model that included the same
variables as the multinomial logistical regression.
3. Results
From December 1st 2003 to January 28th 2008, 411 patients
HCV-RNA positive were submitted to genotyping. Mean age
was 41.1±12.0 years, 56.5% were men and most patients
(73.9%) were from the health regional coordination of Passo
Fundo, a medium size city in south of Brazil.
The proportions of genotypes were 41.5% (95% CI 37.9–
48.1, n = 183) for type 1 (55 subtype 1a and 41 subtype
1b), 19.3% (95% CI 15.0–23.6, n = 85) for type 2, and
39.3% (95% CI 35.6–43.0, n = 173) for type 3. There
was a diﬀerence in genotype 2 distribution when comparing
health centers, with higher genotype 2 prevalence in the
largest city (22.7% versus 9.6%; P = 0.007). Table 1 presentsThe Scientiﬁc World Journal 3
Table 2: Genotype distribution according to risk factors among hepatitis C virus-infected patients from the countryside of southern Brazil
(N and %).
Risk factors N∗ Genotype 1 Genotype 2 Genotype 3 P value∗
Blood transfusion 397
0.160 Yes 50 (36.5) 33 (24.1) 54 (39.4)
No 118 (45.4) 46 (17.7) 96 (36.9)
Use of IV medication 393
0.199 Yes 68 (41.7) 39 (23.9) 56 (34.4)
No 95 (41.3) 40 (17.4) 95 (41.3)
Acupuncture 393
0.726 Yes 4 (30.8) 3 (23.1) 6 (46.2)
No 163 (41.5) 79 (20.1) 151 (38.4)
Hemodialysis 390
0.510 Yes 4 (30.8) 2 (15.4) 7 (53.8)
No 157 (41.6) 77 (20.4) 143 (37.9)
Exposure to blood or organic
secretions 391
0.119
Yes 26 (31.7) 19 (23.2) 37 (45.1)
No 137 (44.3) 58 (18.8) 114 (36.9)
Tatoo 393
0.207 Yes 25 (46.3) 6 (11.1) 23 (42.6)
No 138 (40.7) 73 (21.5) 128 (37.8)
Use of injection drugs 394
0.032 Yes 38 (53.5) 7 (9.9) 26 (36.6)
No 129 (39.9) 71 (22.0) 123 (38.1)
Surgical treatment 393
0.023 Yes 81 (39.5) 52 (25.4) 72 (35.1)
No 82 (43.6) 27 (14.4) 79 (42.0)
Piercing 393
0.643 Yes 4 (40.0) 1 (10.0) 5 (50.0%)
No 159 (41.5) 78 (20.4) 146 (38.1)
Inhalation drug 389
0.028 Yes 32 (53.3) 5 (8.3) 23 (38.3)
No 130 (39.5) 73 (22.2) 126 (38.3)
Dental procedure 394
0.010 Yes 72 (36.7) 51 (26.0) 73 (37.2)
No 92 (46.5) 28 (14.1) 78 (39.4)
Transplant 391
0.287 Yes 1 (25.0) 0 (0.0) 3 (75.0)
No 161 (41.6) 79 (20.4) 147 (38.0)
Percutaneous accident 389
0.979 Yes 7 (43.8) 3 (18.8) 6 (37.5)
No 154 (41.3) 75 (20.1) 144 (38.6)
∗Chi-square test; IV: intravenous.
the genotype distribution according to sociodemographic
characteristics and risk factors. Data regarding genotype,
gender, and age were obtained for all patients. Some other
variables were lost due to incomplete notiﬁcation form
ﬁlling. Genotype 1 was the most prevalent among men,
while among women it was genotype 3 (P = 0.028).
Patients carrying genotype 2 were older (52.2 ± 12.8 years
for type 2, versus 43.6 ± 11.2 years for type 1 and 45.6 ±
11.5 years for type 3; P<0,001), and the prevalence of
nonwhite subjects was lower than in other groups (3.6%
in type 2, versus 13.1% in type 1 and 6.6% in type 3).
Among several established risk factors for HCV infection,4 The Scientiﬁc World Journal
Table 3: Risk factors for genotype 1 and for genotype 3 compared
to genotype 2 in patients with HCV infection in the countryside of
southern Brazil.
RR 95% CI P∗
Genotype 1
Age 0.94 0.91–0.96 <0.001
Education
0–3 years 2.38 0.81–6.57 0.095
4–11 years 1.94 0.89–4.25 0.096
≥12 years 1
Dental procedure
Yes 0.37 0.19–0.70 0.002
No 1
Genotype 3
Age 0.95 0.92–0.97 <0.001
Education
0–3 years 1.98 0.69–5.73 0.206
4–11 years 2.69 1.21–5.98 0.016
≥12 years 1
Dental procedure
Yes 0.48 0.25–0.93 0.029
No 1
∗Multinomial regression adjusted for age, education, skin color, and dental
procedure.
4–11 years education  0.62  (0.4–0.96)
>11 years education   1
>40–60  years old        0.6    (0.38–0.95)
> 60 years old              1
<4 years education     0.79  (0.45–1.37)
18–40  years old           0.38  (0.2–0.7)
Dental procedure        1.75   (1.1–2.79)
PR    (95% CI)
0.3 0.5 0.7 0.9 1.5 1 2.5
Figure 1: Prevalence ratio for genotype type 2 in patients with
hepatitis C in southern Brazil.
use of intravenous and inhalation drugs, surgical treatment,
and dental procedures were associated to the genotype
(Table 2). On the multinomial regression, older age, history
of dental procedure, and higher education increased the risk
for infection by genotype 2 (Table 3). Adjusted prevalence
ratiosareshowninFigure 1.Dentalprocedurewasassociated
with higher prevalence of genotype 2 independently of age,
education and of which treatment center patient came from.
4. Discussion
In this study we observed prevalence of genotypes 1, 2,
and 3 of 41.5%, 19.3%, and 39.2%, respectively, which are
not the same as observed in other regions of the country
and the world. A study conducted in Spanish health centers
[7] described a higher proportion of genotype 1 (65.4%)
and only 3.1% of genotype 2. In Poland [9] there is a
genotype 1 percentage much similar to the one found in this
study, but with a higher genotype 2 (37.8%) and a lower
genotype 3 (23.4%) proportion. In south India genotype
1 was found in only 18.8% of population, and genotype 3
was higher (62.2%) than in this study [24]. Of 284 samples
from the III National Health and Nutrition Examination
Survey, conducted in North and Central America, 275 were
genotyped [25]. As in our study, genotype 1 was the most
common one, but with an even higher prevalence (78.2%;
1a = 51.6% and 1b = 26.6%). Genotypes 2 (12.7%; 2a =
2.9 and 2b = 9.8) and 3 (6.2%) were less common, and
genotypes 4 and 6 were also detected (1.1% and 1.8%, resp.).
In Latin America countries such as Argentina and Venezuela,
genotypes 1 and 2 account for almost 90% of cases [13–15].
In Brazil (Table 4), a study [21] with 1.668 samples col-
lected between 1995 and 2000 in laboratories from diﬀerent
regions detected genotypes 1 (64.9%), 2 (4.6%), 3 (30.2%),
4 (0.2%), and 5 (0.1%). Proportions of each genotype were
signiﬁcantly diﬀerent according to each region, but genotype
1 was always the most common (51.2% to 74.1%). The
southregionshowedalowerproportion ofgenotype1, when
compared to other regions (51.2% versus 57.0 to 74.1%, P =
0.001), and a higher proportion of genotype 3 (40.3% versus
24.7 to 31.6%). This pattern of distribution is similar to the
one we found in the present study. Another study [22]w i t h
patients from several healthcare centers in Brazil included
more participants, being 81% from public institutions and
19% from private practice. Patients mean age was 46 years,
62% were male and 80% were white. Genotypes 1 (64%), 2
(1.3%), 3 (33%), and 4 (1.7%) were identiﬁed. Most patients
werefromthesouthandsoutheastregions,andonly4%were
from the northeast. Once again, there is a higher proportion
of genotype 3 in the south compared to north and northeast
(44% versus 27% and 26%). Genotype 1 was found in 51%
of samples from southeast region and in 71% of samples
from the northeast. Genotype 2 was detected in only 2% of
samples from northeast and southeast, and in 5% of samples
from the south. In the central-west region the prevalence of
genotype 2 was higher (11.4%), but it was still lower than
the one we found in our study (19.3%), which included only
countryside cities. Our ﬁndings also diﬀer from two studies
conducted in Porto Alegre, the capital of state. The ﬁrst
was a retrospective study with 400 patients under treatment
[23] from 1999 to 2000, which described a similar genotype
distribution among men and women and a low prevalence
of genotype 2 (41.3% of genotype 1, 5.0% of genotype 2,
and 53.7% of genotype 3). In the second study [6], genotype
1 was diagnosed in 81.5% of coinfected outpatients in a
HIV/AIDS reference center of the Brazilian public health
system and was associated with male gender. The study
recorded only 1.7% of genotype 2. The higher prevalenceThe Scientiﬁc World Journal 5




Campiotto et al. [21]
85 North 74.1 1.2 24.7 0 0
237 Northeast 66.6 2.9 30.4 0 0
79 Center-west 57.0 11.4 31.6 0 0
1111 Southeast 59.6 3.8 28.4 0.3 0.2
176 South 51.2 8.0 40.3 0 0
1688 Total 64.9 4.6 30.2 0.2 0.1
Focaccia et al. [22]
121 Northeast 71.0 2.0∗ 27.0 NI 0
705 Southeast 72.0 2.0∗ 26.0 NI 0
522 South 51.0 5.0∗ 44.0 NI 0
1348 Total 64.0 1.3 33.0 1.7 0
Alves et al. [23] 400 Porto Alegre-RS 41.3 5.0 53.7 0 0
Wolﬀ et al. [6] 173 Porto Alegre-RS 81.5 1.7 16.2 0 0
∗Genotype 2 plus 4; NI: not informed.
of genotype 3 among women found in our study can be
explained by the older age of this group, since genotype 3
showed a positive and independent association with age.
In Venezuela, increasing genotype 2 prevalence was
described, rising from 26% in 1994–96 to 41% in 2005-
06 [15]. A study conducted in Yucat˜ an, Mexico [26],
described a genotype 2 prevalence of 33.3% signiﬁcantly
associated with family history of liver disease. Factors
positively associated with genotype 2 in our study were age,
higher education, and history of dental procedures. These
characteristics may indicate a higher socioeconomic level,
suggesting a speciﬁc risk proﬁle. Genotype 2 among patients
from Passo Fundo may be associated to socioeconomic
and cultural diﬀerences in comparison to other smaller
cities in the region. Although dental treatment is a known
risk factor for hepatitis B [27], dental procedures include
surgical treatment which represents a potential for HCV
transmission through contaminated injection equipment.
Even oral cavity examination might be involved, since it was
found that sharing personal hygiene objects might explain
the transmission of HCV [6].
Viral load has crucial relevance on the viral transmis-
sion. On crude analysis, there was a statistically signiﬁcant
association between genotype and risk factors for HCV
transmission, as the use of injection and inhalation drugs,
surgical treatment and dental procedures. Despite infected
patients with history of previous exposition to those factors
being more commonly infected by genotype 1, genotype 2
was relatively more frequent in participants with history of
dental procedure (26%) in comparison to other risk factors
(Table 1). These ﬁndings diﬀer from studies with drug users
in Poland [9]a n dS i b e r i a[ 28], which recorded association
between dental procedures and HCV genotype 1. But it
agrees with a study from Lybia that recorded high incidence
of the genotype 2 after surgery and dental procedure [29].
H C Vg e n o t y p ei sap r e d i c t i v ef a c t o rt oa n t i v i r a lt r e a t -
ment response. There are clear evidence [30] indicating that
genotypes 1 and 4 are associated to poor interferon response,
either in single therapy or combined with ribavirin, the
opposite being true for genotypes 2 and 3 treated for 24
weeks. Best treatment results, measured by viral parameters,
are reached within 48 weeks for patients with genotype
2 or 3, while patients with genotype 1 need one year of
treatment. Therefore, long-term beneﬁts of HCV treatment
may be estimated based on the characteristics of the treated
population.
Since HCV treatment has high costs and is provided
by the public health care system for all Brazilian citizens,
we believe that almost all HCV positive patients from that
regional population were included in the studied sample, but
they may be representative of the lower income population.
Although disease register is mandatory, occasionally the
form was incompletely ﬁlled, causing loss of epidemiologic
information and a limitation of our study. The method
limitation to identify genotype subtypes deserves mention,
but this was not an aim of the study and it is still the method
performed in the Brazilian health system and the only one
oﬀered by the public system, in the place wherethe study was
conducted.
In conclusion, in a region from south Brazil the most
common HCV genotype was type 1, followed by type 3,
in accordance to previous reports, but the proportion of
genotype 2 was higher than expected and was signiﬁcantly
associated to history of dental procedures and older age.
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